natgillin/translations-raw huggingface dataset:
M1 and M3 have an open beta-lactone ring and extremely weak lipase inhibitory activity (1,000- and 2,500-fold less than orlistat, respectively).
M1 i M3 sadržavaju otvoreni beta-laktonski prsten i imaju krajnje slabu inhibicijsku aktivnost na lipazu (1000 odnosno 2500 puta manje od orlistata).
M1 is mainly cleared through direct biliary excretion with the contribution of UGT-mediated glucuronidation and, to a small extent, oxidative metabolism.
M1 se uglavnom izlučuje izravnom bilijarnom ekskrecijom, uz doprinos glukuronidacije posredovane UGT- om i u manjoj mjeri oksidativnog metabolizma.
M184V alone
Samo M184V
M184V is associated with about a 2 fold increase in abacavir resistance but does not confer clinical resistance for abacavir.
M184V se povezuje s približno dvostrukim povećanjem rezistencije na abakavir, ali ne uzrokuje kliničku rezistenciju na abakavir.
M184V mutants display greatly reduced susceptibility to lamivudine and show diminished viral replicative capacity in vitro.
Mutanti M148V pokazuju uvelike smanjenu osjetljivost na lamivudin i smanjenu sposobnost virusne replikacije in vitro.
M2’ and M3’, the major metabolites in human faeces, were formed from M2 and lenvatinib, respectively, by aldehyde oxidase.
M2’ i M3’, glavni metaboliti u ljudskoj stolici, nastali su iz M2 odnosno lenvatiniba djelovanjem aldehid oksidaze.
M3-receptors in central versus peripheral airways, beta2-agonists should be more effective in relaxing peripheral airways, whilst an anticholinergic compound may be more effective in central airways.
M3-receptora u središnjim naspram perifernih dišnih puteva, beta2-agonisti trebali bi biti djelotvorniji u opuštanju perifernih dišnih puteva, dok bi antikolinergički spoj mogao biti djelotvorniji u središnjim dišnim putevima.
M72I
M72V
M72R
A73E
M76R
S78X
M76T
A73V
M97-765 is a randomised, double-blind trial evaluating Kaletra at two dose levels (400/100 mg and 400/200 mg, both twice daily) plus nevirapine (200 mg twice daily) and two nucleoside reverse transcriptase inhibitors in 70 single protease inhibitor experienced, non-nucleoside reverse transcriptase inhibitor naïve patients.
M97-765 bilo je randomizirano, dvostruko slijepo ispitivanje dviju doza lijeka Kaletra (400/100 mg i 400/200 mg dvaput na dan u oba slučaja) plus nevirapin (200 mg dvaput na dan) te dvaju nukleozidnih inhibitora reverzne transkriptaze u 70 bolesnika koji su prethodno primali jedan inhibitor proteaze, ali ne i nenukleozidne inhibitore reverzne transkriptaze.
M98-957 is a randomised, open-label study evaluating Kaletra treatment at two dose levels (400/100 mg and 533/133 mg, both twice daily) plus efavirenz (600 mg once daily) and nucleoside reverse transcriptase inhibitors in 57 multiple protease inhibitor experienced, non-nucleoside reverse transcriptase inhibitor naïve patients.
M98-957 bilo je randomizirano, otvoreno ispitivanje dviju doza lijeka Kaletra (400/100 mg i 533/133 mg dvaput na dan u oba slučaja) plus efavirenz (600 mg jedanput na dan) i nukleozidnih inhibitora reverzne transkriptaze u 57 bolesnika koji su ranije primali više inhibitora proteaze, ali ne i nenukleozidne inhibitore reverzne transkriptaze.
m: months
m: mjeseci
MA (EU)
Broj (EU) odobrenja
MA (EU)  number
Broj (EU) odobrenja
MA (EU) number
Broj (EU)
MA (EU) number
Broj (EU) odobrenja (Zaštićeno)
MA (EU) number
EU/1/15/1012/058
MA (EU) number (Invented)
EU/1/07/431/020
MA 01605 USA
MA 01605 SAD
MA 01701-9322 USA
MA 01701-9322 SAD
MA 01757 UNITED STATES
MA 01757 SAD
MA 02141 USA
MA 02141 SAD
MabThera (N=167)
MabThera
MabThera +MTX 2 × 1000 mg
MabThera + metotreksat 2 x 1000 mg
MabThera 100 mg concentrate for solution for infusion
MabThera 100 mg koncentrat za otopinu za infuziju
MabThera 100 mg concentrate for solution for infusion rituximab
MabThera 100 mg koncentrat za otopinu za infuziju rituksimab
MabThera 1400 mg is used to treat Non-Hodgkin’s lymphoma in adults.
MabThera 1400 mg se koristi za liječenje ne-Hodgkinova limfoma kod odraslih.
MabThera 1400 mg solution for subcutaneous injection
MabThera 1400 mg otopina za supkutanu injekciju
MabThera 1400 mg solution for subcutaneous injection rituximab subcutaneous
MabThera 1400 mg otopina za supkutanu injekciju rituksimab supkutano
MabThera 1400 mg subcutaneous formulation should be administered as subcutaneous injection only, over approximately 5 minutes.
MabThera od 1400 mg u formulaciji za supkutanu primjenu smije se primijeniti isključivo u obliku supkutane injekcije tijekom približno 5 minuta.
MabThera 1600 mg solution for subcutaneous injection
MabThera 1600 mg otopina za supkutanu injekciju
MabThera 1600 mg solution for subcutaneous injection rituximab subcutaneous
MabThera 1600 mg otopina za supkutanu injekciju rituksimab supkutano
MabThera 1600 mg subcutaneous formulation should be administered as subcutaneous injection only, over approximately 7 minutes.
MabThera od 1600 mg u formulaciji za supkutanu primjenu smije se primijeniti isključivo u obliku supkutane injekcije tijekom približno 7 minuta.
MabThera 500 mg concentrate for solution for infusion
MabThera 500 mg koncentrat za otopinu za infuziju
MabThera 500 mg concentrate for solution for infusion Rituximab
MabThera 500 mg koncentrat za otopinu za infuziju rituksimab
MabThera Alert Card for patients with non-oncology diseases
MabThera kartica s upozorenjima za bolesnike s neonkološkim bolestima
MabThera at 375 mg/m2 body surface area given every 2 months until disease progression or for a maximum period of two years.
375 mg/m2 tjelesne površine svaka 2 mjeseca do progresije bolesti ili najdulje dvije godine.
MabThera at a fixed dose of 1600 mg was administered for 5 cycles subcutaneously at 4-weekly intervals, following the first cycle of MabThera intravenous formulation, in previously untreated CLL patients in combination with chemotherapy (fludarabine and cyclophosphamide (FC).
MabThera u fiksnoj dozi od 1600 mg primjenjivala se supkutano tijekom 5 ciklusa u 4-tjednim intervalima, nakon prvog ciklusa liječenja formulacijom lijeka MabThera za intravensku primjenu, u kombinaciji s kemoterapijom (fludarabin i ciklofosfamid, FC) u prethodno neliječenih bolesnika s KLL-om.
MabThera contains the active substance rituximab.
Lijek MabThera sadrži djelatnu tvar rituksimab.
MabThera has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Pokazalo se da MabThera u kombinaciji s metotreksatom usporava napredovanje oštećenja zglobova, ocijenjeno radiografski te poboljšava fizičku funkciju.
MabThera has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.
Pokazalo se da MabThera u kombinaciji s metotreksatom usporava napredovanje oštećenja zglobova, ocijenjeno radiografski, te poboljšava fizičku funkciju.
MabThera in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes-.
MabThera u kombinaciji s kemoterapijom uništava te stanice, koje se postupno uklanjaju iz tijela biološkim procesima.
MabThera in combination with chemotherapy destroys these cells which are gradually removed from the body by biological processes.
MabThera u kombinaciji s kemoterapijom uništava te stanice koje se postupno uklanjaju iz tijela biološkim procesima.
MabThera in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.
MabThera je u kombinaciji s metotreksatom indicirana za liječenje odraslih bolesnika s teškim oblikom aktivnog reumatoidnog artritisa koji nisu dovoljno dobro odgovorili na druge antireumatske lijekove koji modificiraju tijek bolesti (engl. disease-modifying anti-rheumatic drugs, DMARDs), uključujući jedan ili više inhibitora faktora nekroze tumora (TNF), ili ih nisu podnosili.
MabThera in combination with methotrexate significantly increased the proportion of patients achieving at least a 20 % improvement in ACR score compared with patients treated with methotrexate alone (Table 10).
MabThera je u kombinaciji s metotreksatom znatno povećala udio bolesnika koji su postigli najmanje 20%-tno poboljšanje ACR rezultata u usporedbi s bolesnicima koji su liječeni samo metotreksatom (Tablica 10).
MabThera in combination with methotrexate significantly increased the proportion of patients achieving at least a 20% improvement in ACR score compared with patients treated with methotrexate alone (Table 10).
MabThera je u kombinaciji s metotreksatom znatno povećala udio bolesnika koji su postigli najmanje 20%-tno poboljšanje ACR rezultata u usporedbi s bolesnicima koji su liječeni samo metotreksatom (Tablica 10).
MabThera infusions were administered after an intravenous infusion of 100 mg methylprednisolone; patients also received treatment with oral prednisone for 15 days.
Infuzije lijeka MabThera primjenjivane su nakon intravenske infuzije 100 mg metilprednizolona; bolesnici su također peroralno primali prednizon u trajanju od 15 dana.
MabThera intravenous (n= 88): 1st cycle of MabThera intravenous 375 mg/m2 in combination with chemotherapy followed by up to 5 cycles of MabThera intravenous 500 mg/m2 in combination with chemotherapy.
MabThera u formulaciji za intravensku primjenu (n=88): u 1. ciklusu primjenjivala se intravenska formulacija lijeka MabThera u dozi od 375 mg/m2 u kombinaciji s kemoterapijom, nakon čega je uslijedilo do 5 ciklusa liječenja formulacijom lijeka MabThera za intravensku primjenu u dozi od 500 mg/m2 u kombinaciji s kemoterapijom.
MabThera intravenous formulation (n= 205): 8 cycles of MabThera intravenous formulation in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks.
MabThera u formulaciji za intravensku primjenu (n=205): 8 ciklusa lijeka MabThera u formulaciji za intravensku primjenu u kombinaciji s najviše 8 ciklusa CHOP ili CVP kemoterapije primijenjene svaka 3 tjedna.
MabThera intravenous formulation was used at the standard dose of 375 mg/m2 body surface area.
MabThera u formulaciji za intravensku primjenu davala se u standardnoj dozi od 375 mg/m2 površine tijela.
MabThera is a medicine used to treat the following blood cancers and inflammatory conditions:
MabThera je lijek koji se koristi za liječenje sljedećih vrsta raka krvi i upala:
MabThera is associated with infusion related reactions (IRRs), which may be related to release of cytokines and/or other chemical mediators.
MabThera se povezuje s reakcijama na infuziju, koje mogu biti posljedica otpuštanja citokina i/ili drugih kemijskih medijatora.
MabThera is associated with infusion/ related reactions, which may be related to release of cytokines and/or other chemical mediators.
Primjena lijeka MabThera povezuje se s reakcijama na infuziju, koje mogu biti povezane s otpuštanjem citokina i/ili drugih kemijskih medijatora.
MabThera is associated with infusionrelated reactions, which may be related to release of cytokines and/or other chemical mediators.
Primjena lijeka MabThera povezuje se s reakcijama na infuziju, koje mogu biti povezane s otpuštanjem citokina i/ili drugih kemijskih medijatora.
MabThera is available as a concentrate that is made up into the solution for infusion and as a ready- made solution for the injection under the skin.
Lijek MabThera dostupan je u obliku koncentrata od kojeg se priprema otopina za infuziju i kao gotova otopina za injekciju pod kožu.
MabThera is available as a medicine given as a drip (called MabThera 100 mg or MabThera 500 mg, concentrate for solution for infusion) and as a medicine for injection under your skin: called MabThera 1400 mg or MabThera 1600 mg, solution for subcutaneous injection).
MabThera je dostupna kao lijek koji se daje ukapavanjem u venu (MabThera 100 mg ili MabThera 500 mg, koncentrat za otopinu za infuziju) i kao lijek koji se injicira pod kožu (MabThera 1400 mg ili MabThera 1600 mg, otopina za supkutanu injekciju).
MabThera is given as an infusion (drip) into a vein.
Lijek MabThera daje se kao infuzija (drip) u venu.
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
MabThera je u kombinaciji s CHOP kemoterapijom (ciklofosfamid, doksorubicin, vinkristin, prednizolon) indicirana u liječenju bolesnika s CD20 pozitivnim difuznim ne-Hodgkinovim limfomom velikih B-stanica.
MabThera is indicated in adults for Non-Hodgkin’s lymphoma (NHL):
MabThera je indicirana u odraslih osoba za ne-Hodgkinov limfom (NHL):
MabThera is indicated in adults for the following indications: Non-Hodgkin’s lymphoma (NHL)
MabThera je indicirana u odraslih u sljedećim indikacijama: Ne-Hodgkinov limfom (NHL)
MabThera is indicated in adults in combination with chemotherapy for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL).
MabThera je u kombinaciji s kemoterapijom indicirana za liječenje odraslih bolesnika s prethodno neliječenom i relapsirajućom/refraktornom kroničnom limfocitnom leukemijom (KLL).
MabThera is used for inducing remission in granulomatosis with polyangiitis (formerly called Wegener’s granulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids.
MabThera se u kombinaciji s kortikosteroidima primjenjuje za poticanje remisije granulomatoze s poliangitisom (ranije se zvala Wegenerova granulomatoza) i mikroskopskog poliangitisa.
MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
Terapija održavanja lijekom MabThera indicirana je u liječenju bolesnika oboljelih od folikularnog limfoma koji su odgovorili na uvodnu terapiju.
MabThera maintenance treatment consisted of a single infusion of
Terapija održavanja lijekom MabThera sastojala se od jedne infuzije lijeka MabThera u dozi od
MabThera maintenance treatment consisted of a single infusion of MabThera at 375 mg/m2 body surface area given every 3 months until disease progression or for a maximum period of two years.
Terapija održavanja lijekom MabThera sastojala se od primjene jedne infuzije lijeka MabThera u dozi od 375 mg/m2 tjelesne površine svaka tri mjeseca do progresije bolesti ili najdulje dvije godine.
MabThera maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (< 60 years, >= 60 years), FLIPI score (<=1, 2 or >= 3), induction therapy (R-CHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR, CRu or PR).
Terapija održavanja lijekom MabThera donijela je dosljednu korist u svim unaprijed definiranim ispitanim podskupinama: s obzirom na spol (muški, ženski), dob (< 60 godina, >= 60 godina), FLIPI indeks (<= 1, 2 ili >= 3) i početnu terapiju (R-CHOP, R-CVP ili R-FCM) te bez obzira na kvalitetu odgovora na početnu terapiju (CR/CRu ili PR).
MabThera maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (< 60 years, >= 60 years), FLIPI score (<=1, 2 or >= 3), induction therapy (R-CHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR/CRu or PR).
Terapija održavanja lijekom MabThera donijela je dosljednu korist u svim unaprijed definiranim ispitanim podskupinama: s obzirom na spol (muški, ženski), dob (< 60 godina, >= 60 godina), FLIPI indeks (<= 1, 2 ili >= 3) i indukcijsku terapiju (R-CHOP, R-CVP ili R-FCM) te bez obzira na kvalitetu odgovora na početnu terapiju (CR/CRu ili PR).
MabThera maintenance treatment provided consistent benefit in all predefined subgroups tested: gender (male, female), age (60 years, >= 60 years), FLIPI score (<=1, 2 or >= 3), induction therapy (R-CHOP, R-CVP or R-FCM) and regardless of the quality of response to induction treatment (CR,CRu or PR).
Terapija održavanja lijekom MabThera donijela je dosljednu korist u svim unaprijed definiranim ispitanim podskupinama: s obzirom na spol (muški, ženski), dob (< 60 godina, >= 60 godina), FLIPI indeks (<= 1, 2 ili >= 3) i početnu terapiju (R-CHOP, R-CVP ili R-FCM) te bez obzira na kvalitetu odgovora na početnu terapiju (CR/CRu ili PR).
MabThera maintenance treatment reduced the risk of death by 56 % (95 % CI; 22 %-75 %).
Terapija održavanja lijekom MabThera smanjila je rizik od smrti za 56% (95% CI 22%-75%).
MabThera must not be used in people who are hypersensitive (allergic) to rituximab, mouse proteins or any of the other ingredients or in patients with a severe infection or a severely weakened immune system.
Lijek MabThera ne smije se primjenjivati u osoba koje su preosjetljive (alergične) na rituksimab, mišje bjelančevine ili bilo koje druge sastojke lijeka ili u bolesnika s jakom infekcijom ili značajno oslabljenim imunološkim sustavom.
MabThera N=505
MabThera N = 505
MabThera rituximab
MabThera rituksimab
MabThera should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3) or severely immunocompromised patients (e.g. where levels of CD4 or CD8 are very low).
MabThera se ne smije primijeniti bolesnicima s aktivnom teškom infekcijom (npr. tuberkulozom, sepsom i oportunističkim infekcijama, vidjeti dio 4.3) ili teško imunokompromitiranim bolesnicima (npr. kada su razine CD4 ili CD8 stanica vrlo niske).
MabThera subcutaneous (n= 88); 1st cycle of MabThera intravenous 375 mg/m2 in combination with chemotherapy plus subsequent cycles (2-6) of MabThera subcutaneous 1600mg in combination with chemotherapy.
MabThera u formulaciji za supkutanu primjenu (n=88): u 1. ciklusu primjenjivala se intravenska formulacija lijeka MabThera u dozi od 375 mg/m2 u kombinaciji s kemoterapijom, a zatim se u sljedećim ciklusima (2. – 6.) primjenjivala formulacija lijeka MabThera za supkutanu primjenu u dozi od 1600 mg u kombinaciji s kemoterapijom.
MabThera subcutaneous formulation (n= 205): first cycle MabThera intravenous formulation plus 7 cycles of MabThera subcutaneous formulation in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks.
MabThera u formulaciji za supkutanu primjenu (n=205): u prvom ciklusu primjenjivala se MabThera u formulaciji za intravensku primjenu, a zatim je uslijedilo još 7 ciklusa u kojima se primjenjivala MabThera u formulaciji za supkutanu primjenu u kombinaciji s najviše 8 ciklusa CHOP ili CVP kemoterapije primijenjene svaka 3 tjedna.
MabThera subcutaneous formulation contains recombinant human hyaluronidase (rHuPH20), an enzyme used to increase the dispersion and absorption of co-administered substances when administered subcutaneously.
Formulacija lijeka MabThera za supkutanu primjenu sadrži rekombinantnu humanu hijaluronidazu (rHuPH20), enzim koji se koristi za povećanje disperzije i apsorpcije istodobno primijenjenih lijekova kada se oni primjenjuju supkutano.
MabThera will be given to you on the same day as your chemotherapy.
Lijek MabThera primit ćete istoga dana kad i kemoterapiju.
MabThera, administered as an intravenous infusion at a dose of 375 mg/m2 at weekly intervals for 4 doses to 203 patients with NHL naive to MabThera, yielded a mean Cmax following the fourth infusion of 486 µg/mL (range, 77.5 to 996.6 µg/mL).
Srednja vrijednost Cmax nakon četvrte intravenske infuzije lijeka MabThera u dozi od 375 mg/m2, u razmacima od tjedan dana u 203 bolesnika s NHL-om koji prethodno nisu primali lijek MabThera, iznosila je 486 µg/ml (raspon od 77,5 do 996,6 µg/ml).
MabThera, in combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).
MabThera je u kombinaciji s glukokortikoidima indicirana za poticanje remisije u odraslih bolesnika s teškom aktivnom granulomatozom s poliangitisom (Wegenerova granulomatoza) (GPA) i mikroskopskim poliangitisom (MPA).
Macclesfield, Cheshire SK10 2NA United Kingdom
Macclesfield, Cheshire SK10 2NA Velika Britanija
Macclesfield, Cheshire, SK10 2NA United Kingdom
Macclesfield, Cheshire, SK10 2NA Ujedinjeno Kraljevstvo
MACE confirmed by adjudication were reported in 52 of 3182 (1.6%) patients in the alirocumab group and 33 of 1792 (1.8%) patients in the control group (placebo or active control); HR=0.81 (95% CI, 0.52 to 1.25).
Neovisno potvrđeni MACE događaji bili su prijavljeni u 52 od 3182 (1,6%) bolesnika u skupini liječenoj alirokumabom te 33 od 1792 (1,8%) bolesnika u kontrolnoj skupini (placebo ili aktivni kontrolni lijek); HR=0,81 (95% CI: 0,52 – 1,25).
MACE Reported in cardiovascular outcomes study
MACE prijavljeni u ispitivanju kardiovaskularnih ishoda
MACI 500,000 - 1,000,000 cells/cm2 implantation matrix
MACI 500 000 - 1 000 000 stanica/cm2 matriks za implantaciju
MACI 500,000 - 1,000,000 cells/cm2 implantation matrix Matrix applied characterised autologous cultured chondrocytes
MACI 500 000 - 1 000 000 stanica/cm2 matriks za implantaciju kultivirani karakterizirani autologni hondrociti aplicirani na matriks
MACI 500,000 to 1,000,000 cells/cm2 implantation matrix
MACI 500 000 do 1 000 000 stanica/cm2 matriks za implantaciju
MACI has been investigated in a parallel, randomised, open-label trial in 144 patients with Outerbridge Grade III or IV focal cartilage defects of the knee of 3-20 cm2 (median 4 cm2).
MACI je ispitan u paralelnom, randomiziranom, otvorenom ispitivanju sa 144 bolesnika s fokalnim oštećenjem hrskavice koljena stupnja III ili IV prema Outerbridgeovoj ljestvici te površine 3-20 cm2 (medijan 4 cm2).
MACI is an advanced therapy product called a ‘tissue engineered product’.
Implantat MACI je vrsta lijeka za naprednu terapiju koji se naziva „lijek dobiven tkivnim inženjerstvom”.
MACI is an implant consisting of a porcine derived (derived from pigs) collagen membrane which contains your own cartilage cells (called autologous chondrocytes) and is implanted into your knee.
MACI je implantat koji se sastoji od kolagene membrane svinjskoga podrijetla koja sadrži Vaše vlastite stanice hrskavice (koje se zovu autologni hondrociti), a usađuje se u koljeno.
MACI is indicated for the repair of symptomatic, full-thickness cartilage defects of the knee (grade III and IV of the Modified Outerbridge Scale) of 3-20 cm2 in skeletally mature adult patients.
MACI je indiciran za popravak simptomatskih oštećenja čitave debljine hrskavice koljena (stupnja III i IV prema modificiranoj Outerbridgeovoj ljestvici) površine 3-20 cm2, u koštano zrelih odraslih bolesnika.
MACI must be administered by a surgeon specifically trained and qualified in the use of MACI.
MACI smije primijeniti isključivo kirurg koji je posebno obučen i kvalificiran za primjenu implantata MACI.
MACI must only be implanted by surgeons who have been specifically trained for this kind of surgery.
MACI smiju implantirati samo kirurzi koji su posebno obučeni za ovu vrstu kirurškoga zahvata.
MACI will be released following successful results from assays which assess chondrocyte viability, identity, potency, minimum cell number, endotoxin, pre-release sterility, and mycoplasma.
MACI se pušta u promet nakon povoljnih rezultata testova kojima se ocjenjuju vijabilnost hondrocita, identitet, potentnost i minimalan broj stanica, endotoksini, sterilnost prije puštanja u promet te mikoplazma.
Macitentan and its active metabolite
Macitentan i njegov aktivni metabolit
Macitentan and its active metabolite are not inhibitors of hepatic or renal efflux pumps at clinically relevant concentrations, including the multi-drug resistance protein (P-gp, MDR-1) and multidrug and toxin extrusion transporters (MATE1 and MATE2-K).
Macitentan i njegov aktivni metabolit nisu inhibitori jetrenih ili bubrežnih efluksnih pumpi pri klinički relevantnim koncentracijama uključujući protein rezistencije na više lijekova (multidrug resistance protein; P-gp, MDR-1) i ekstruzijske transportere više lijekova i toksina (MATE1 i MATE2-K).